In the news

Bloxam Hill
29 May 2012

Introducing our new one-day in-house workshop

Leveraging patient reported outcome (PRO) measures throughout the Product Lifecycle – A Case Study in Diabetes

In addition to the clinical outcomes, understanding the benefits of a new drug for Type 1 and Type 2 diabetes from the perspective of the patient is critical. Held at a time and venue suitable for your organisation for up 16 delegates, this highly interactive one day workshop will enable participants to gain a deeper insight into the value associated with the use of PROs in Phase II to Late Phase studies.

  • Understand how disease-specific and generic PROs have been used in diabetes drug development to date – Losses and gains
  • Assess the value of PROs in each stage of product development
  • Learn why PRO endpoints are essential for effective drug development and evaluation
  • Identify the essential components e.g. domains required for the PRO
  • Understand the relationship between primary clinical endpoints e.g. HbA1c and PRO scores
  • Learn how and when PROs should be implemented in the product lifecycle

 For more information contact

For all press and media enquiries please contact